IL-18 Inhibits Growth of Murine Prostate Cancer
Author Information
Author(s): Tse Brian Wan-Chi, Russell Pamela Joan, Lochner Matthias, Förster Irmgard, Power Carl Andrew
Primary Institution: University of New South Wales
Hypothesis
Can IL-18 serve as an effective immunotherapy for prostate cancer?
Conclusion
IL-18 significantly inhibits the growth of prostate tumors through both adaptive and innate immune mechanisms.
Supporting Evidence
- IL-18 significantly inhibited the growth of both subcutaneous and orthotopic RM1 tumors.
- Neutralization of IL-18 resulted in significantly larger tumors.
- IL-18 treatment correlated with increased infiltration of CD8+ and CD4+ T cells in tumors.
Takeaway
IL-18 helps the body fight prostate cancer by boosting the immune system, making tumors smaller or preventing them from growing.
Methodology
The study used murine models of prostate cancer, implanting tumor cells that express IL-18 and assessing tumor growth with and without IL-18 neutralization.
Limitations
The study was conducted in murine models, which may not fully replicate human responses.
Participant Demographics
Male C57BL/6 mice, 4-6 weeks old.
Statistical Information
P-Value
p=0.0002
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website